Skip to content
Attacking IBD Through a Novel Pathway episode artwork

Jan 17, 2019 19 min

Attacking IBD Through a Novel Pathway

from The Bio Report Hosted by Levine Media Group

Current therapies for autoimmune diseases represent a $100 billion market, but available drugs often provide limited benefits to patients or cause problematic side effects. Landos Biopharma is targeting the area of autoimmune diseases with an initial focus on inflammatory bowel disease by pursuing therapies that target a novel pathway. We spoke to Landos founder and CEO Josep Bassaganya-Riera, about IBD, why new therapies are needed, and the approach Landos is taking.

Episode details come from the podcast's RSS feed.

Embed this episode

Ready to play

Attacking IBD Through a Novel Pathway

0:00 19:36

No transcript yet.

Requests help us decide what to transcribe next.

Frequently asked questions

How long is this episode of The Bio Report?

This episode is 19 minutes long.

When was this The Bio Report episode published?

This episode was published on January 17, 2019.

Can I download this The Bio Report episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.